By Benjamin Horney (July 14, 2016, 3:49 PM EDT) -- Israel-based Teva Pharmaceuticals Industries Ltd. plans to raise as much as $25 billion to help finance its roughly $40.5 billion acquisition of Allergan PLC's generics business, Reuters reported on Thursday. According to the report, Teva plans to hold investor calls in the U.S. soon, with meetings in Europe to be scheduled shortly after, as the company readies for the planned bond sale. Barclays PLC, Bank of America Merrill Lynch, BNP Paribas, Credit Suisse Group, HSBC Bank PLC and Mizuho Bank Ltd. are helping set up the calls and meetings, the report noted, and the bond offering will likely come in multiple currencies, including the U.S. dollar, the euro and possibly the Swiss franc....